



**Stanley Fahn, MD** is the H. Houston Merritt Professor of Neurology and Director of the Center for Parkinson's Disease and Other Movement Disorders at Columbia University. He is the Scientific Director of the Parkinson's Disease Foundation. He served as President of the American Academy of Neurology (AAN) from 2001-2003. In 1985, he founded and served as the Chairman of the Steering Committee of the Movement Disorder Society, an international organization of professionals active in this subspecialty. After its constitution was approved, he was elected its first president. He was the founding co-editor of the journal *Movement Disorders*, and served in this capacity for the first 10

years of the journal's existence, until 1996. He has also served as Associate Editor of *Neurology* for 10 years. Dr. Fahn has twice served as Chairman of the Advisory Committee on Peripheral and Central Nervous System Drugs for the Food and Drug Administration. With Dr. Ira Shoulson, Dr. Fahn co-founded in 1986 the Parkinson Study Group (PSG), a consortium of clinical investigators dedicated to conduct controlled clinical trials on the prevention and treatment of Parkinson's disease. Dr. Fahn was elected and re-elected as Co-Chair of its Executive Committee and served for 20 years in that capacity.

He organized and executed the development of the Unified Parkinson's Disease Rating Scale (UPDRS) and modified and popularized the use of the Schwab-England ADL scoring for global severity of this disease. He participated in clinical trials with the Parkinson Study Group of many pharmacotherapeutic agents for PD, including the ELLDOPA trial to study the effect of levodopa therapy on the natural history of PD, funded by NIH and published in 2004. For this work, he was co-winner of the triennial Anne-Marie Opprecht Foundation Parkinson Award in 2005 for the most outstanding scientific work on Parkinson's disease published in the years 2002-2004. Another notable trial was the first controlled surgical trial for fetal tissue transplantation for patients with advanced PD. NIH selected Dr. Fahn to deliver the 2000 Neurodegeneration Lecture, and he was asked by NIH to serve on its Oversight Committee to review and give advice on clinical trials on neuroprotection for PD. Dr. Fahn and his scientific colleagues at Columbia University were awarded a Morris K. Udall Parkinson's Disease Research Center of Excellence by the National Institutes of Health in 1999, and it is currently ongoing with Dr. Robert Burke as the current director. He was selected to be Chairman and chief organizer of the first ever World Parkinson Congress that was held in Washington, DC, in February 2006. He is currently co-organizing the second World Parkinson Congress, to be held in Glasgow, Scotland, in September 2010.

The American Academy of Neurology honored him with the Wartenberg Award for outstanding clinical research in 1986, the First Movement Disorder Prize for outstanding contributions in this field in 1997, and their A. B. Baker Award for outstanding educator in neurology in 1996. The American Neurological Association awarded him the First Soriano Lectureship for excellence in research. In October 2007, he received the James Parkinson Medal, awarded once every 10 years by the Parkinson's Disease Foundation. In October 2002, Dr. Fahn was elected a member of the Institute of Medicine of the U.S. National Academies. Dr. Fahn continues to be active in patient



care, research and teaching and has trained over 120 Movement Disorder Fellows, including many who are professors of neurology around the globe. September 2007 saw the publication by Elsevier of a textbook on movement disorders, entitled *Principles and Practice of Movement Disorders*, Dr. Fahn co-authored with Dr. Joseph Jankovic.

Representative Publications:

**Fahn S**, Elton RL, Members of the UPDRS Development Committee. The Unified Parkinson's Disease Rating Scale. In Fahn S, Marsden CD, Calne DB, Goldstein M, eds: Recent Developments in Parkinson's Disease, Vol. 2. Florham Park, NJ: Macmillan Healthcare Information, 1987. pp. 153-163, 293-304.

Freed CR, Greene PE, Breeze RE, Tsai W-Y, DuMouchel W, Kao R, Dillon S, Winfield H, Culver S, Trojanowski JQ, Eidelberg D, **Fahn S**. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. *N Engl J Med* 2001;344:710-719.

**Fahn S**, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K; Parkinson Study Group. Levodopa and the progression of Parkinson's disease. *N Engl J Med* 2004;Dec 9;351(24):2498-2508.

**Fahn S**, Jankovic J. Principles and Practice of Movement Disorders. Philadelphia, Churchill Livingstone Elsevier, 2007.